CNO Financial Group (CNO) 2024 KBW Insurance Conference summary
Event summary combining transcript, slides, and related documents.
2024 KBW Insurance Conference summary
22 Jan, 2026Strategic evolution and growth
Transitioned from a focus on fixing and stabilizing to positioning as a growth story, with eight to nine quarters of demonstrated progress.
Unique focus on the middle market, serving consumers with net worths below $100,000, differentiating from competitors.
Diversified business model with consumer and worksite divisions, and a broad product mix including life, annuities, and Medicare products.
Integrated captive agent and direct-to-consumer channels, with one-third of agent sales sourced from D2C leads.
Worksite business enhanced by bolt-on acquisitions, though full potential of technology and advice platforms is still being realized.
Agent productivity and distribution
Shifted emphasis from agent recruitment to productivity and retention, resulting in higher agent success and lower turnover.
Increased reliance on personal referrals and support structures for agents, with a growing number holding securities licenses.
Broker-dealer established, enabling agents to offer broader financial services and annuities, with customer assets reaching $12–15 billion.
Direct-to-consumer and agent channels work synergistically, with seamless lead handoffs and a growing share of non-TV advertising.
Product strategy and performance
Medicare Supplement product relaunched in 2022, leading to strong sales growth; now represents 14 Medicare Advantage carriers.
Short-term care products dominate long-term care offerings, with 90% of policies having benefit periods of one year or less.
Long-term care risk de-risked via a 2018 reinsurance deal; retained book is low risk, with less than 3% lifetime benefits and high average attained age.
Continued expansion into retirement products and advisory services, moving upmarket within the middle segment.
Latest events from CNO Financial Group
- Record premiums, 11% EPS growth, and strong capital returns highlight robust 2025 results.CNO
Q4 20256 Feb 2026 - Operating EPS up 94%, guidance raised, and strong growth in sales and agent productivity.CNO
Q2 20242 Feb 2026 - Operating earnings and annuity sales surged, prompting raised 2024 guidance and strong capital returns.CNO
Q3 202417 Jan 2026 - Operating EPS up 52%, guidance reaffirmed, and capital strength and buybacks continued.CNO
Q1 202524 Dec 2025 - Record earnings, sales, and capital returns in 2024, with strong ROE and growth outlook.CNO
Q4 202422 Dec 2025 - Record financial performance, robust governance, and key plan amendments drive 2025 proxy agenda.CNO
Proxy Filing1 Dec 2025 - Record financial results, increased shareholder returns, and key governance votes mark 2025's agenda.CNO
Proxy Filing1 Dec 2025 - Director elections, compensation, auditor ratification, and ESG initiatives headline the agenda.CNO
Proxy Filing1 Dec 2025 - Premium growth and capital returns offset lower net income, supporting ROE targets.CNO
Q2 202516 Nov 2025